COT-13 OUTCOMES OF MEDULLOBLASTOMA IN KOBE CHILDREN,S HOSPITAL OVER THE RECENT 11 YEARS


 
 
 Medulloblastoma is the most frequent malignant brain tumor in children, which 5-year survival rate have improved to 70-85%. In this study, we retrospectively reviewed outcomes and late complications of 31 medulloblastoma cases treated at our institute from 2010 to 2021.
 
 
 
 The mean age of the cases was 6.5 years. 22 cases were total resection and 17 were judged to be in the high-risk group. With respect to histopathological diagnosis, 23 cases were classified as classic type, 2 as desmoplastic/nodular type, 2 as with extensive nodularity type, and 4 as anaplastic/large cell type. As for molecular analysis, WNT was 2, SHH was 3 , Group 3 was 3, Group 4 was 8 cases. One case was lost due to relocation.
 
 
 
 21 patients have no recurrence of medulloblastoma, but two were victims of second cancers. The remaining 19 cases were all in the standard-risk group and survived with a complete reaction (CR). There were 9 cases of recurrence (including disseminated disease) and the survived case after retreatment was only one in the high-risk group which indicated CR.
 
 
 
 The 5-year survival rate for patients in standard-risk group at our institution was 92.3%, indicating improved outcomes. The poor prognosis group could be divided in group who developed recurrence or second cancers after 5 years or more and group who indicated insufficient reaction to multimodality treatment and died around 2 years after diagnosis. As late complications, there were 5 cases of higher functional impairment, who were 16.7% of whole cases and almost in the high-risk group. It is necessary to pursue further treatment for the high-risk group and to recognize that the number of survivors of medulloblastoma cases is increasing, and to support for the AYA generation.
